Conditions: Relapsing Remitting Multiple Sclerosis
Keywords: Multiple Sclerosis Relapsing Remitting Multiple Sclerosis (RRMS) Glatiramer Acetate (GA)
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 147
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare pain associated with injections and injection-site reactions of the approved formulation of Glatiramer Acetate (GA) versus investigational formulation of GA. In addition, the investigators will evaluate the side effects of the two formulations of GA.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Glatiramer Acetate intervention 2: Experimental Glatiramer Acetate
Intervention descriptions: intervention 1: Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary. intervention 2: GA 20 mg/0.5 mL

Protocol document: